The DOI matches its Crossref record; 32 of the 32 references it cites were found in a registry or an index.
Mutant TP53 Posttranslational Modifications: Challenges and Opportunities
Abstract
The wild-type (WT) human p53 (TP53) tumor suppressor can be posttranslationally modified at over 60 of its 393 residues. These modifications contribute to changes in TP53 stability and in its activity as a transcription factor in response to a wide variety of intrinsic and extrinsic stresses in part through regulation of protein-protein and protein-DNA interactions. The TP53 gene frequently is mutated in cancers, and in contrast to most other tumor suppressors, the mutations are mostly missense often resulting in the accumulation of mutant (MUT) protein, which may have novel or altered functions. Most MUT TP53s can be posttranslationally modified at the same residues as in WT TP53. Strikingly, however, codons for modified residues are rarely mutated in human tumors, suggesting that TP53 modifications are not essential for tumor suppression activity. Nevertheless, these modifications might alter MUT TP53 activity and contribute to a gain-of-function leading to increased metastasis and tumor progression. Furthermore, many of the signal transduction pathways that result in TP53 modifications are altered or disrupted in cancers. Understanding the signaling pathways that result in TP53 modification and the functions of these modifications in both WT TP53 and its many MUT forms may contribute to more effective cancer therapies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In the case of mutant p53, these modifications may further alter its functional and kinetic properties, thereby affecting its behavior in tumorigenesis and progression.170”
From p53: from understanding its structure to advances in therapeutic targeting (2026) · cites this paper as [170]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Blinded by the Light: The Growing Complexity of p53
Vousden, K. H., & Prives, C. (2009) · Cell · doi:10.1016/j.cell.2009.04.037 · Cited by 3,163
Crystal Structure of a p53 Tumor Suppressor-DNA Complex: Understanding Tumorigenic Mutations
Cho, Y., Gorina, S., Jeffrey, P. D., & Pavletich, N. P. (1994) · Science · doi:10.1126/science.8023157 · Cited by 2,551 · cited 1×
“Among the mutations in this domain, about 30% locate within six “hotspot” residues that are frequent in almost all cancer types [Hollstein et al., 1991; Cho et al., 1994], for example, Arg175, Gly245, Arg248, Arg249, Arg273, and Arg282, but which are not known to be posttranslationally modified.”
BackgroundDNA damage-induced phosphorylation of p53 alleviates inhibition by MDM2
Shieh, S.-Y., Ikeda, M., Taya, Y., & Prives, C. (1997) · Cell · doi:10.1016/s0092-8674(00)80416-x · Cited by 2,100
Transcriptional control of human p53-regulated genes
Riley, T., Sontag, E., Chen, P., & Levine, A. (2008) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm2395 · Cited by 1,921
Kruse, J.-P., & Gu, W. (2009) · Cell · doi:10.1016/j.cell.2009.04.050 · Cited by 1,610 · cited 4×
“Most of the lysine residues subject to acetylation can also be modified by methylation, Ub, and neddylation, all of which have inhibitory effects on a variety of TP53 functions [Kruse and Gu, 2009b].”
BackgroundInfluentialPetitjean, A., Mathe, E., Kato, S., Ishioka, C., Tavtigian, S. V., Hainaut, P., & Olivier, M. (2007) · Human Mutation · doi:10.1002/humu.20495 · Cited by 1,598 · cited 3×
“Alteration of the TP53 gene itself or perturbations in TP53 signaling pathways are the most frequent events in tumorigenesis [Petitjean et al., 2007] and can be considered hallmarks of cancer cells [Pfeifer and Hainaut, 2011].”
BackgroundMutant p53 gain of function in two mouse models of Li-Fraumeni syndrome
Olive, K. P., Tuveson, D. A., Ruhe, Z. C., Yin, B., Willis, N. A., Bronson, R. T., Crowley, D., & Jacks, T. (2004) · Cell · doi:10.1016/j.cell.2004.11.004 · Cited by 1,308
Regulating the p53 pathway: in vitro hypotheses, in vivo veritas
Toledo, F., & Wahl, G. M. (2006) · Nature reviews. Cancer · doi:10.1038/nrc2012 · Cited by 1,286
MDM2, MDMX and p53 in oncogenesis and cancer therapy
Wade, M., Li, Y.-C., & Wahl, G. M. (2013) · Nature Reviews Cancer · doi:10.1038/nrc3430 · Cited by 1,279
Post-translational modification of p53 in tumorigenesis
Bode, A. M., & Dong, Z. (2004) · Nature Reviews Cancer · doi:10.1038/nrc1455 · Cited by 1,270
DNA damage activates p53 through a phosphorylation–acetylation cascade
Sakaguchi, K., Herrera, J. E., Saito, S., Miki, T., Bustin, M., Vassilev, A., Anderson, C. W., & Appella, E. (1998) · Genes & Development · doi:10.1101/gad.12.18.2831 · Cited by 1,204
Self-citationWhen mutants gain new powers: News from the mutant p53 field
Brosh, R., & Rotter, V. (2009) · Nature Reviews Cancer · doi:10.1038/nrc2693 · Cited by 1,132
Gain of function of a p53 hot spot mutation in a mouse model of Li-Fraumeni syndrome
Lang, G. A., Iwakuma, T., Suh, Y.-A., Liu, G., Rao, V. A., Parant, J. M., Valentin-Vega, Y. A., Terzian, T., Caldwell, L. C., Strong, L. C., et al. (2004) · Cell · doi:10.1016/j.cell.2004.11.006 · Cited by 1,069
Shared and separate functions of polo-like kinases and aurora kinases in cancer
Lens, S. M. A., Voest, E. E., & Medema, R. H. (2010) · Nature Reviews Cancer · doi:10.1038/nrc2964 · Cited by 597
The expanding universe of p53 targets
Menendez, D., Inga, A., & Resnick, M. A. (2009) · Nature Reviews Cancer · doi:10.1038/nrc2730 · Cited by 568
Self-citationAcetylation of p53 inhibits its ubiquitination by Mdm2
Li, M., Luo, J., Brooks, C. L., & Gu, W. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.c200578200 · Cited by 503
p53 and its mutants in tumor cell migration and invasion
Muller, P. A. J., Vousden, K. H., & Norman, J. C. (2011) · Journal of Cell Biology · doi:10.1083/jcb.201009059 · Cited by 463
The p53 orchestra: Mdm2 and Mdmx set the tone
Wade, M., Wang, Y. V., & Wahl, G. M. (2010) · Trends in Cell Biology · doi:10.1016/j.tcb.2010.01.009 · Cited by 450
The pathological response to DNA damage does not contribute to p53-mediated tumour suppression
Christophorou, M. A., Ringshausen, I., Finch, A. J., Swigart, L. B., & Evan, G. I. (2006) · Nature · doi:10.1038/nature05077 · Cited by 382
Emerging roles for chromatin as a signal integration and storage platform
Badeaux, A. I., & Shi, Y. (2013) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm3545 · Cited by 291
The multiple levels of regulation by p53 ubiquitination
Lee, J. T., & Gu, W. (2010) · Cell Death & Differentiation · doi:10.1038/cdd.2009.77 · Cited by 289
Feng, L., Lin, T., Uranishi, H., Gu, W., & Xu, Y. (2005) · Molecular and Cellular Biology · doi:10.1128/mcb.25.13.5389-5395.2005 · Cited by 236 · cited 5×
“…are crucial for tumor suppression based on data from mice having the C-terminal six or seven lysines substituted by arginine (K6R, 7KR) as described above [Feng et al., 2005; Krummel, et al., 2005], the dysregulation of these modifications might well contribute to tumor initiation or progression.”
BackgroundInfluentialUbiquitination and Degradation of Mutant p53
Lukashchuk, N., & Vousden, K. H. (2007) · Molecular and Cellular Biology · doi:10.1128/mcb.00050-07 · Cited by 223
Krummel, K. A., Lee, C. J., Toledo, F., & Wahl, G. M. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0503068102 · Cited by 187
Gain-of-function mutations of PPM1D/Wip1 impair the p53-dependent G1 checkpoint
Kleiblova, P., Shaltiel, I. A., Benada, J., Ševčík, J., Pecháčková, S., Pohlreich, P., Voest, E. E., Dundr, P., Bartek, J., Kleibl, Z., et al. (2013) · Journal of Cell Biology · doi:10.1083/jcb.201210031 · Cited by 170
Phosphorylation of Serine 18 Regulates Distinct p53 Functions in Mice
Sluss, H. K., Armata, H., Gallant, J., & Jones, S. N. (2004) · Molecular and Cellular Biology · doi:10.1128/mcb.24.3.976-984.2004 · Cited by 152
Cell Type- and Promoter-specific Roles of Ser18 Phosphorylation in Regulating p53 Responses
Chao, C., Hergenhahn, M., Kaeser, M. D., Wu, Z., Saito, S., Iggo, R., Hollstein, M., Appella, E., & Xu, Y. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m306938200 · Cited by 141
Defective apoptosis and B-cell lymphomas in mice with p53 point mutation at Ser 23
MacPherson, D., Kim, J., Kim, T., Rhee, B. K., van Oostrom, C. T., DiTullio, R. A., Venere, M., Halazonetis, T. D., Bronson, R., de Vries, A., et al. (2004) · The EMBO Journal · doi:10.1038/sj.emboj.7600363 · Cited by 124 · cited 2×
“Only three studies showed increases in spontaneous tumor formation and decreased lifespan as compared with TP53 WT mice [MacPherson et al., 2004; Chao et al., 2006a; Armata et al., 2007].”
BackgroundResultIncreased Sensitivity to UV Radiation in Mice with a p53 Point Mutation at Ser389
Bruins, W., Zwart, E., Attardi, L. D., Iwakuma, T., Hoogervorst, E. M., Beems, R. B., Miranda, B., van Oostrom, C. T. M., van den Berg, J., van den Aardweg, G. J., et al. (2004) · Molecular and Cellular Biology · doi:10.1128/mcb.24.20.8884-8894.2004 · Cited by 121
Isolation of Temperature-sensitive p53 Mutations from a Comprehensive Missense Mutation Library
Shiraishi, K., Kato, S., Han, S.-Y., Liu, W., Otsuka, K., Sakayori, M., Ishida, T., Takeda, M., Kanamaru, R., Ohuchi, N., et al. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m310815200 · Cited by 96
Extensive Post-translational Modification of Active and Inactivated Forms of Endogenous p53
DeHart, C. J., Chahal, J. S., Flint, S. J., & Perlman, D. H. (2014) · Molecular & Cellular Proteomics · doi:10.1074/mcp.m113.030254 · Cited by 70
Yakovlev, V. A., Bayden, A. S., Graves, P. R., Kellogg, G. E., & Mikkelsen, R. B. (2010) · Biochemistry · doi:10.1021/bi100564w · Cited by 56
Research works printed but not linked: 147
- Acs, 2011, The AAA-ATPase VCP/p97 promotes 53BP1 recruitment by removing L3MBTL1 from DNA double-strand breaks, Nat Struct Mol Biol, 18, 1345, 10.1038/nsmb.2188 · DOI · Paper page
- Adorno, 2009, A mutant-p53/Smad complex opposes p63 to empower TGFβ-induced metastasis, Cell, 137, 87, 10.1016/j.cell.2009.01.039 · DOI · Paper page
- Anderson, 2009, Handbook of cell signaling, 2185
- Armata, 2007, The ataxia telangiectasia-mutated target site Ser18 is required for p53-mediated tumor suppression, Cancer Res, 67, 11696, 10.1158/0008-5472.CAN-07-1610 · DOI
- Armata, 2010, Requirement of the ATM/p53 tumor suppressor pathway for glucose homeostasis, Mol Cell Biol, 30, 5787, 10.1128/MCB.00347-10 · DOI
- Bar, 2009, Expression of p53 protein phosphorylated at serine 20 and serine 392 in malignant and benign ovarian neoplasms: correlation with clinicopathological parameters of tumors, Int J Gynecol Cancer, 19, 1322, 10.1111/IGC.0b013e3181b70465 · DOI
- Bartkova, 2007, DNA damage response mediators MDC1 and 53BP1: constitutive activation and aberrant loss in breast and lung cancer, but not in testicular germ cell tumours, Oncogene, 26, 7414, 10.1038/sj.onc.1210553 · DOI
- Bech-Otschir, 2001, COP9 signalosome-specific phosphorylation targets p53 to degradation by the ubiquitin system, EMBO J, 20, 1630, 10.1093/emboj/20.7.1630 · DOI · Paper page
- Bensimon, 2011, Beyond ATM: the protein kinase landscape of the DNA damage response, FEBS Lett, 585, 1625, 10.1016/j.febslet.2011.05.013 · DOI · Paper page
- Berger, 2005, Mutations in proline 82 of p53 impair its activation by Pin1 and Chk2 in response to DNA damage, Mol Cell Biol, 25, 5380, 10.1128/MCB.25.13.5380-5388.2005 · DOI
- Brooks, 2003, Ubiquitination, phosphorylation and acetylation: the molecular basis for p53 regulation, Curr Opin Cell Biol, 15, 164, 10.1016/S0955-0674(03)00003-6 · DOI · Paper page
- Burns, 2003, Silencing of the novel p53 target gene Snk/Plk2 leads to mitotic catastrophe in paclitaxel (taxol)-exposed cells, Mol Cell Biol, 23, 5556, 10.1128/MCB.23.16.5556-5571.2003 · DOI · Paper page
- Campaner, 2011, The methyltransferase Set7/9 (Setd7) is dispensable for the p53-mediated DNA damage response in vivo, Mol Cell, 43, 681, 10.1016/j.molcel.2011.08.007 · DOI
- Carr, 2012, Lysine methylation and the regulation of p53, Essays Biochem, 52, 79, 10.1042/bse0520079 · DOI
- Carter, 2009, Modifications of p53: competing for the lysines, Curr Opin Genet Dev, 19, 18, 10.1016/j.gde.2008.11.010 · DOI
- Chao, 2006a, Ser18 and 23 phosphorylation is required for p53-dependent apoptosis and tumor suppression, EMBO J, 25, 2615
- Chao, 2006b, Acetylation of mouse p53 at lysine 317 negatively regulates p53 apoptotic activities after DNA damage, Mol Cell Biol, 26, 6859, 10.1128/MCB.00062-06 · DOI
- Coffill, 2012, Mutant p53 interactome identifies nardilysin as a p53R273H-specific binding partner that promotes invasion, EMBO Rep, 13, 638, 10.1038/embor.2012.74 · DOI
- Collavin, 2010, p53-family proteins and their regulators: hubs and spokes in tumor suppression, Cell Death Differ, 17, 901, 10.1038/cdd.2010.35 · DOI · Paper page
- Cordenonsi, 2007, Integration of TGF-β and Ras/MAPK signaling through p53 phosphorylation, Science, 315, 840, 10.1126/science.1135961 · DOI · Paper page
- Cui, 2012, PHF20 is an effector protein of p53 double lysine methylation that stabilizes and activates p53, Nat Struct Mol Biol, 19, 916, 10.1038/nsmb.2353 · DOI
- Dai, 2010, p53 post-translational modification: deregulated in tumorigenesis, Trends Mol Med, 16, 528, 10.1016/j.molmed.2010.09.002 · DOI · Paper page
- Dai, 2013, Negative regulation of the acetyltransferase TIP60-p53 interplay by UHRF1 (ubiquitin-like with PHD and RING Finger Domains 1), J Biol Chem, 288, 19581, 10.1074/jbc.M113.476606 · DOI
- Dai, 2011, Differential effects on p53-mediated cell cycle arrest vs. apoptosis by p90, Proc Natl Acad Sci U S A, 108, 18937, 10.1073/pnas.1110988108 · DOI
- Debnath, 2011, Peptide-protein interactions suggest that acetylation of lysines 381 and 382 of p53 is important for positive coactivator 4-p53 interaction, J Biol Chem, 286, 25076, 10.1074/jbc.M110.205328 · DOI
- Donehower, 2014, Insights into wildtype and mutant p53 functions provided by genetically engineered mice, Hum Mutat, 35, 715, 10.1002/humu.22507 · DOI
- Donehower, 2009, 20 years studying p53 functions in genetically engineered mice, Nat Rev Cancer, 9, 831, 10.1038/nrc2731 · DOI · Paper page
- Elston, 2012, Crosstalk between p53 and TGF-β signalling, J Signal Transduct, 2012, 294097, 10.1155/2012/294097 · DOI
- Emamzadah, 2011, Crystal structure of a multidomain human p53 tetramer bound to the natural CDKN1A (p21) p53-response element, Mol Cancer Res, 9, 1493, 10.1158/1541-7786.MCR-11-0351 · DOI
- Endicott, 2012, The structural basis for control of eukaryotic protein kinases, Annu Rev Biochem, 81, 587, 10.1146/annurev-biochem-052410-090317 · DOI · Paper page
- Feng, 2006, Ser46 phosphorylation regulates p53-dependent apoptosis and replicative senescence, Cell Cycle, 5, 2812, 10.4161/cc.5.23.3526 · DOI
- Ferreon, 2009, Cooperative regulation of p53 by modulation of ternary complex formation with CBP/p300 and HDM2, Proc Natl Acad Sci USA, 106, 6591, 10.1073/pnas.0811023106 · DOI · Paper page
- Freeman, 2013, The impact of post-transcriptional regulation in the p53 network, Brief Funct Genomics, 12, 46, 10.1093/bfgp/els058 · DOI
- Furihata, 2002, Frequent phosphorylation at serine 392 in overexpressed p53 protein due to missense mutation in carcinoma of the urinary tract, J Pathol, 197, 82, 10.1002/path.1082 · DOI
- Gardino, 2011, 14-3-3 proteins as signaling integration points for cell cycle control and apoptosis, Semin Cell Dev Biol, 22, 688, 10.1016/j.semcdb.2011.09.008 · DOI · Paper page
- Gillotin, 2010, Mutation at Ser392 specifically sensitizes mutant p53H175 to mdm2-mediated degradation, Cell Cycle, 9, 1390, 10.4161/cc.9.7.11253 · DOI
- Girardini, 2011, A Pin1/mutant p53 axis promotes aggressiveness in breast cancer, Cancer Cell, 20, 79, 10.1016/j.ccr.2011.06.004 · DOI · Paper page
- Goh, 2011, The role of mutant p53 in human cancer, J Pathol, 223, 116, 10.1002/path.2784 · DOI · Paper page
- Gu, 2012, Surf the post-translational modification network of p53 regulation, Int J Biol Sci, 8, 672, 10.7150/ijbs.4283 · DOI · Paper page
- Haupt, 2009, Promyelocytic leukemia protein is required for gain of function by mutant p53, Cancer Res, 69, 4818, 10.1158/0008-5472.CAN-08-4010 · DOI
- Hock, 2010, Regulation of the p53 pathway by ubiquitin and related proteins, Int J Biochem Cell Biol, 42, 1618, 10.1016/j.biocel.2010.06.011 · DOI
- Hollstein, 1991, p53 mutations in human cancers, Science, 253, 49, 10.1126/science.1905840 · DOI · Paper page
- Hoogervorst, 2005, Lack of p53 Ser389 phosphorylation predisposes mice to develop 2-acetylaminofluorene-induced bladder tumors but not ionizing radiation-induced lymphomas, Cancer Res, 65, 3610, 10.1158/0008-5472.CAN-04-4328 · DOI
- Huang, 2007, p53 is regulated by the lysine demethylase LSD1, Nature, 449, 105, 10.1038/nature06092 · DOI · Paper page
- Huang, 2012, Global tumor protein p53/p63 interactome: making a case for cisplatin chemoresistance, Cell Cycle, 11, 2367, 10.4161/cc.20863 · DOI
- Hupp, 1995, Two distinct signaling pathways activate the latent DNA binding function of p53 in a casein kinase II-independent manner, J Biol Chem, 270, 18165, 10.1074/jbc.270.30.18165 · DOI
- Iwabuchi, 1994, Two cellular proteins that bind to wild-type but not mutant p53, Proc Natl Acad Sci USA, 91, 6098, 10.1073/pnas.91.13.6098 · DOI · Paper page
- Jansson, 2008, Arginine methylation regulates the p53 response, Nat Cell Biol, 10, 1431, 10.1038/ncb1802 · DOI · Paper page
- Jeffrey, 1995, Crystal structure of the tetramerization domain of the p53 tumor suppressor at 1.7 angstroms, Science, 267, 1498, 10.1126/science.7878469 · DOI · Paper page
- Jenkins, 2012, p53 N-terminal phosphorylation: a defining layer of complex regulation, Carcinogenesis, 33, 1441, 10.1093/carcin/bgs145 · DOI
- Jenkins, 2008, Quantitative proteomics analysis of the effects of ionizing radiation in wild type and p53K317R knock-in mouse thymocytes, Mol Cell Proteomics, 7, 716, 10.1074/mcp.M700482-MCP200 · DOI
- Jiang, 2011, Full p53 transcriptional activation potential is dispensable for tumor suppression in diverse lineages, Proc Natl Acad Sci USA, 108, 17123, 10.1073/pnas.1111245108 · DOI
- Kachirskaia, 2008, Role for 53BP1 tudor domain recognition of p53 dimethylated at lysine 382 in DNA damage signaling, J Biol Chem, 283, 34660, 10.1074/jbc.M806020200 · DOI
- Kamada, 2011, Cancer-associated p53 tetramerization domain mutants: quantitative analysis reveals a low threshold for tumor suppressor inactivation, J Biol Chem, 286, 252, 10.1074/jbc.M110.174698 · DOI
- Kato, 2003, Understanding the function-structure and function-mutation relationships of p53 tumor suppressor protein by high-resolution missense mutation analysis, Proc Natl Acad Sci USA, 100, 8424, 10.1073/pnas.1431692100 · DOI · Paper page
- Keller, 2001, A DNA damage-induced p53 serine 392 kinase complex contains CK2, hSpt16, and SSRP1, Mol Cell, 7, 283, 10.1016/S1097-2765(01)00176-9 · DOI · Paper page
- Kim, 2012, Functional interplay between p53 acetylation and H1.2 phosphorylation in p53-regulated transcription, Oncogene, 31, 4290, 10.1038/onc.2011.605 · DOI
- Kruse, 2009a, MSL2 promotes Mdm2-independent cytoplasmic localization of p53, J Biol Chem, 284, 3250, 10.1074/jbc.M805658200 · DOI
- Kulikov, 2006, Binding of p53 to the central domain of Mdm2 is regulated by phosphorylation, J Biol Chem, 281, 28575, 10.1074/jbc.M513311200 · DOI
- Kurash, 2008, Methylation of p53 by Set7/9 mediates p53 acetylation and activity in vivo, Mol Cell, 29, 392, 10.1016/j.molcel.2007.12.025 · DOI · Paper page
- Kurimchak, 2013, PP2A counterbalances phosphorylation of pRB and mitotic proteins by multiple CDKs: potential implications for PP2A disruption in cancer, Genes Cancer, 3, 739, 10.1177/1947601912473479 · DOI
- Lane, 2010, Mdm2 and p53 are highly conserved from placozoans to man, Cell Cycle, 9, 540, 10.4161/cc.9.3.10516 · DOI
- Latronico, 2001, An inherited mutation outside the highly conserved DNA-binding domain of the p53 tumor suppressor protein in children and adults with sporadic adrenocortical tumors, J Clin Endocrinol Metab, 86, 4970, 10.1210/jcem.86.10.7957 · DOI · Paper page
- Lee, 2010, Graded enhancement of p53 binding to CREB-binding protein (CBP) by multisite phosphorylation, Proc Natl Acad Sci USA, 107, 19290, 10.1073/pnas.1013078107 · DOI · Paper page
- Lee, 2012, Cell-type, dose, and mutation-type specificity dictate mutant p53 functions in vivo, Cancer Cell, 22, 751, 10.1016/j.ccr.2012.10.022 · DOI
- Lee, 2011, Serine 312 phosphorylation is dispensable for wild-type p53 functions in vivo, Cell Death Differ, 18, 214, 10.1038/cdd.2010.90 · DOI
- Lehnertz, 2011, p53-dependent transcription and tumor suppression are not affected in Set7/9-deficient mice, Mol Cell, 43, 673, 10.1016/j.molcel.2011.08.006 · DOI
- Leroy, 2013, The TP53 website: an integrative resource centre for the TP53 mutation database and TP53 mutant analysis, Nucleic Acids Res, 41, D962, 10.1093/nar/gks1033 · DOI · Paper page
- Li, 2007, An acetylation switch in p53 mediates holo-TFIID recruitment, Mol Cell, 28, 408, 10.1016/j.molcel.2007.09.006 · DOI
- Li, 2011, Functional inactivation of endogenous MDM2 and CHIP by HSP90 causes aberrant stabilization of mutant p53 in human cancer cells, Mol Cancer Res, 9, 577, 10.1158/1541-7786.MCR-10-0534 · DOI · Paper page
- Li, 2012, Tumor suppression in the absence of p53-mediated cell-cycle arrest, apoptosis, and senescence, Cell, 149, 1269, 10.1016/j.cell.2012.04.026 · DOI · Paper page
- Li, 2013, PKB-mediated PHF20 phosphorylation on Ser291 is required for p53 function in DNA damage, Cell Signal, 25, 74, 10.1016/j.cellsig.2012.09.009 · DOI
- Lin, 2005, p53 induces differentiation of mouse embryonic stem cells by suppressing Nanog expression, Nat Cell Biol, 7, 165, 10.1038/ncb1211 · DOI · Paper page
- Liou, 2011, Prolyl isomerase Pin1 as a molecular switch to determine the fate of phosphoproteins, Trends Biochem Sci, 36, 501, 10.1016/j.tibs.2011.07.001 · DOI · Paper page
- Liu, 2013, Functional p53 determines docetaxel sensitivity in prostate cancer cells, Prostate, 73, 418, 10.1002/pros.22583 · DOI
- Liu, 2004, Aurora-A abrogation of p53 DNA binding and transactivation activity by phosphorylation of serine 215, J Biol Chem, 279, 52175, 10.1074/jbc.M406802200 · DOI · Paper page
- Loughery, 2013, Switching on p53: an essential role for protein phosphorylation, BioDiscovery, 8, 1
- Lozano, 2007, The oncogenic roles of p53 mutants in mouse models, Curr Opin Genet Dev, 17, 66, 10.1016/j.gde.2006.12.003 · DOI
- Lu, 2008, The type 2C phosphatase Wip1: an oncogenic regulator of tumor suppressor and DNA damage response pathways, Cancer Metastasis Rev, 27, 123, 10.1007/s10555-008-9127-x · DOI · Paper page
- MacLaine, 2009, The regulation of p53 by phosphorylation: a model for how distinct signals integrate into the p53 pathway, Aging (Albany NY), 1, 490, 10.18632/aging.100047 · DOI
- Maki, 1999, Oligomerization is required for p53 to be efficiently ubiquitinated by MDM2, J Biol Chem, 274, 16531, 10.1074/jbc.274.23.16531 · DOI
- Mantovani, 2007, The prolyl isomerase Pin1 orchestrates p53 acetylation and dissociation from the apoptosis inhibitor iASPP, Nat Struct Mol Biol, 14, 912, 10.1038/nsmb1306 · DOI
- Matsumoto, 2004a, Phosphorylation state of tumor-suppressor gene p53 product overexpressed in skin tumors, Oncol Rep, 12, 1039
- Matsumoto, 2004b, Prognostic significance of serine 392 phosphorylation in overexpressed p53 protein in human esophageal squamous cell carcinoma, Oncology, 67, 143, 10.1159/000081001 · DOI
- Matsumoto, 2006, Posttranslational phosphorylation of mutant p53 protein in tumor development, Med Mol Morphol, 39, 79, 10.1007/s00795-006-0320-0 · DOI
- Meek, 2009, Tumour suppression by p53: a role for the DNA damage response, Nat Rev Cancer, 9, 714, 10.1038/nrc2716 · DOI · Paper page
- Meek, 2009, Posttranslational modification of p53: cooperative integrators of function, Cold Spring Harb Perspect Biol, 1, a000950, 10.1101/cshperspect.a000950 · DOI · Paper page
- Mellert, 2007, The ARF/oncogene pathway activates p53 acetylation within the DNA binding domain, Cell Cycle, 6, 1304, 10.4161/cc.6.11.4343 · DOI
- Melnikova, 2003, Mutant p53 is constitutively phosphorylated at Serine 15 in UV-induced mouse skin tumors: involvement of ERK1/2 MAP kinase, Oncogene, 22, 5958, 10.1038/sj.onc.1206595 · DOI
- Midgley, 1997, p53 protein stability in tumour cells is not determined by mutation but is dependent on Mdm2 binding, Oncogene, 15, 1179, 10.1038/sj.onc.1201459 · DOI · Paper page
- Minamoto, 2001, Distinct pattern of p53 phosphorylation in human tumors, Oncogene, 20, 3341, 10.1038/sj.onc.1204458 · DOI
- Muller, 2013, p53 mutations in cancer, Nat Cell Biol, 15, 2, 10.1038/ncb2641 · DOI · Paper page
- Nagata, 1999, The stabilization mechanism of mutant-type p53 by impaired ubiquitination: the loss of wild-type p53 function and the hsp90 association, Oncogene, 18, 6037, 10.1038/sj.onc.1202978 · DOI
- Noon, 2011, 53BP1-mediated DNA double strand break repair: insert bad pun here, DNA Repair (Amst), 10, 1071, 10.1016/j.dnarep.2011.07.012 · DOI
- Odell, 2013, A novel p53 mutant found in iatrogenic urothelial cancers is dysfunctional and can be rescued by a second-site global suppressor mutation, J Biol Chem, 288, 16704, 10.1074/jbc.M112.443168 · DOI · Paper page
- Okaichi, 2011, Phosphorylation of p53 modifies sensitivity to ionizing radiation, Anticancer Res, 31, 2255
- Ou, 2005, p53 C-terminal phosphorylation by CHK1 and CHK2 participates in the regulation of DNA-damage-induced C-terminal acetylation, Mol Biol Cell, 16, 1684, 10.1091/mbc.E04-08-0689 · DOI · Paper page
- Park, 2012, Identification of Akt interaction protein PHF20/TZP that transcriptionally regulates p53, J Biol Chem, 287, 11151, 10.1074/jbc.M111.333922 · DOI
- Patel, 2013, Readout of epigenetic modifications, Annu Rev Biochem, 82, 81, 10.1146/annurev-biochem-072711-165700 · DOI · Paper page
- Perez, 2010, Restoration of DNA-binding and growth-suppressive activity of mutant forms of p53 via a PCAF-mediated acetylation pathway, J Cell Physiol, 225, 394, 10.1002/jcp.22285 · DOI
- Pfeifer, 2011, Next-generation sequencing: emerging lessons on the origins of human cancer, Curr Opin Oncol, 23, 62, 10.1097/CCO.0b013e3283414d00 · DOI
- Pietenpol, 1994, Sequence-specific transcriptional activation is essential for growth suppression by p53, Proc Natl Acad Sci USA, 91, 1998, 10.1073/pnas.91.6.1998 · DOI · Paper page
- Pietsch, 2007, The tetramerization domain of p53 is required for efficient BAK oligomerization, Cancer Biol Ther, 6, 1576, 10.4161/cbt.6.10.4719 · DOI
- Puca, 2009, Regulation of p53 activity by HIPK2: molecular mechanisms and therapeutical implications in human cancer cells, Oncogene, 29, 4378, 10.1038/onc.2010.183 · DOI
- Ray, 2012, The DNA binding and accumulation of p53 from breast cancer cell lines and the link with serine 15 phosphorylation, Cancer Biol Ther, 13, 848, 10.4161/cbt.20835 · DOI
- Resnick, 2003, Functional mutants of the sequence-specific transcription factor p53 and implications for master genes of diversity, Proc Natl Acad Sci USA, 100, 9934, 10.1073/pnas.1633803100 · DOI · Paper page
- Ribeiro, 2001, An inherited p53 mutation that contributes in a tissue-specific manner to pediatric adrenal cortical carcinoma, Proc Natl Acad Sci USA, 98, 9330, 10.1073/pnas.161479898 · DOI · Paper page
- Rinn, 2011, To repress or not to repress: This is the guardian's question, Trends Cell Biol, 21, 344, 10.1016/j.tcb.2011.04.002 · DOI
- Rodriguez, 2012, Dietary downregulation of mutant p53 levels via glucose restriction: mechanisms and implications for tumor therapy, Cell Cycle, 11, 4436, 10.4161/cc.22778 · DOI
- Rokudai, 2013, MOZ increases p53 acetylation and premature senescence through its complex formation with PML, Proc Natl Acad Sci USA, 110, 3895, 10.1073/pnas.1300490110 · DOI
- Roy, 2010, Structural insight into p53 recognition by the 53BP1 tandem Tudor domain, J Mol Biol, 398, 489, 10.1016/j.jmb.2010.03.024 · DOI
- Sabapathy, 2012, Role of the JNK pathway in human diseases, Prog Mol Biol Transl Sci, 106, 145, 10.1016/B978-0-12-396456-4.00013-4 · DOI
- Saito, 2003, Phosphorylation site interdependence of human p53 post-translational modifications in response to stress, J Biol Chem, 278, 37536, 10.1074/jbc.M305135200 · DOI · Paper page
- Sakaguchi, 1997, Phosphorylation of serine 392 stabilizes the tetramer formation of tumor suppressor protein p53, Biochemistry, 36, 10117, 10.1021/bi970759w · DOI · Paper page
- Schumacher, 2010, Structure of the p53 C-terminus bound to 14-3-3: implications for stabilization of the p53 tetramer, FEBS Lett, 584, 1443, 10.1016/j.febslet.2010.02.065 · DOI
- Serrano, 2013, DNA-PK, ATM and ATR collaboratively regulate p53-RPA interaction to facilitate homologous recombination DNA repair, Oncogene, 32, 2452, 10.1038/onc.2012.257 · DOI
- Slee, 2010, Phosphorylation of Ser312 contributes to tumor suppression by p53 in vivo, Proc Natl Acad Sci USA, 107, 19479, 10.1073/pnas.1005165107 · DOI
- Sluss, 2010, Phosphorylation of p53 serine 18 upregulates apoptosis to suppress Myc-induced tumorigenesis, Mol Cancer Res, 8, 216, 10.1158/1541-7786.MCR-09-0324 · DOI
- Song, 2007, p53 gain-of-function cancer mutants induce genetic instability by inactivating ATM, Nat Cell Biol, 9, 573, 10.1038/ncb1571 · DOI · Paper page
- Stebbing, 2013, The regulatory roles of phosphatases in cancer, Oncogene
- Strebhardt, 2010, Multifaceted polo-like kinases: drug targets and antitargets for cancer therapy, Nat Rev Drug Discov, 9, 643, 10.1038/nrd3184 · DOI · Paper page
- Sugikawa, 1999, Inhibition of mutant p53 phosphorylation at serine 15 or serine 315 partially restores the function of wild-type p53, Biochem Biophys Res Commun, 261, 256, 10.1006/bbrc.1999.1019 · DOI
- Tang, 2008, Acetylation is indispensable for p53 activation, Cell, 133, 612, 10.1016/j.cell.2008.03.025 · DOI · Paper page
- Terzian, 2008, The inherent instability of mutant p53 is alleviated by Mdm2 or p16INK4a loss, Genes Dev, 22, 1337, 10.1101/gad.1662908 · DOI · Paper page
- Teufel, 2009, Regulation by phosphorylation of the relative affinities of the N-terminal transactivation domains of p53 for p300 domains and Mdm2, Oncogene, 28, 2112, 10.1038/onc.2009.71 · DOI · Paper page
- Theuerkorn, 2011, Prolyl cis/trans isomerase signalling pathways in cancer, Curr Opin Pharmacol, 11, 281, 10.1016/j.coph.2011.03.007 · DOI
- Timofeev, 2013, p53 DNA binding cooperativity is essential for apoptosis and tumor suppression in vivo, Cell Rep, 3, 1512, 10.1016/j.celrep.2013.04.008 · DOI
- Trojer, 2007, L3MBTL1, a histone-methylation-dependent chromatin lock, Cell, 129, 915, 10.1016/j.cell.2007.03.048 · DOI · Paper page
- Ullrich, 1993, Phosphorylation at Ser-15 and Ser-392 in mutant p53 molecules from human tumors is altered compared to wild-type p53, Proc Natl Acad Sci USA, 90, 5954, 10.1073/pnas.90.13.5954 · DOI
- Valente, 2013, p53 efficiently suppresses tumor development in the complete absence of its cell-cycle inhibitory and proapoptotic effectors p21, Puma, and Noxa, Cell Rep, 3, 1339, 10.1016/j.celrep.2013.04.012 · DOI · Paper page
- Valenti, 2011, Mutant p53 oncogenic functions are sustained by Plk2 kinase through an autoregulatory feedback loop, Cell Cycle, 10, 4330, 10.4161/cc.10.24.18682 · DOI
- Dieck, 2009, Posttranslational modifications affect the interaction of S100 proteins with tumor suppressor p53, J Mol Biol, 394, 922, 10.1016/j.jmb.2009.10.002 · DOI
- Vogelstein, 2013, Cancer genome landscapes, Science, 339, 1546, 10.1126/science.1235122 · DOI · Paper page
- Warnock, 2008, Influence of tetramerisation on site-specific post-translational modifications of p53: comparison of human and murine p53 tumor suppressor protein, Cancer Biol Ther, 7, 1481, 10.4161/cbt.7.9.6473 · DOI
- Warnock, 2011, Aurora A mediates cross-talk between N- and C-terminal post-translational modifications of p53, Cancer Biol Ther, 12, 1059, 10.4161/cbt.12.12.18141 · DOI
- Waterman, 1998, ATM-dependent activation of p53 involves dephosphorylation and association with 14-3-3 proteins, Nat Genet, 19, 175, 10.1038/542 · DOI · Paper page
- West, 2011, Regulation of p53 function by lysine methylation, Epigenomics, 3, 361, 10.2217/epi.11.21 · DOI
- West, 2010, The MBT repeats of L3MBTL1 link SET8-mediated p53 methylation at lysine 382 to target gene repression, J Biol Chem, 285, 37725, 10.1074/jbc.M110.139527 · DOI
- Wiech, 2012, Molecular mechanism of mutant p53 stabilization: the role of HSP70 and MDM2, PLoS One, 7, e51426, 10.1371/journal.pone.0051426 · DOI · Paper page
- Xu, 2012, Mechanistic links between ATM and histone methylation codes during DNA repair, Prog Mol Biol Transl Sci, 110, 263, 10.1016/B978-0-12-387665-2.00010-9 · DOI
- Yang, 2009, Plk1-mediated phosphorylation of Topors regulates p53 stability, J Biol Chem, 284, 18588, 10.1074/jbc.C109.001560 · DOI
- Yap, 2004, Ser392 phosphorylation regulates the oncogenic function of mutant p53, Cancer Res, 64, 4749, 10.1158/0008-5472.CAN-1305-2 · DOI
- You, 2012, Cancer genetics and epigenetics: two sides of the same coin, Cancer Cell, 22, 9, 10.1016/j.ccr.2012.06.008 · DOI · Paper page
- Zannini, 2012, DBC1 phosphorylation by ATM/ATR inhibits SIRT1 deacetylase in response to DNA damage, J Mol Cell Biol, 4, 294, 10.1093/jmcb/mjs035 · DOI
- Zerbini, 2005, Blockage of NF-κB induces serine 15 phosphorylation of mutant p53 by JNK kinase in prostate cancer cells, Cell Cycle, 4, 1247, 10.4161/cc.4.9.1966 · DOI
- Zhu, 2012, Wip1-dependent signaling pathways in health and diseases, Prog Mol Biol Transl Sci, 106, 307, 10.1016/B978-0-12-396456-4.00001-8 · DOI
- Zilfou, 2009, Tumor suppressive functions of p53, Cold Spring Harb Perspect Biol, 1, a001883, 10.1101/cshperspect.a001883 · DOI · Paper page
Cited by
Mutant p53 as a guardian of the cancer cell
Mantovani, F., Collavin, L., & Del Sal, G. (2019) · Cell Death & Differentiation · doi:10.1038/s41418-018-0246-9 · Cited by 775
Integrated Analysis of TP53 Gene and Pathway Alterations in The Cancer Genome Atlas
Donehower, L. A., Soussi, T., Korkut, A., Liu, Y., Schultz, A., Cardenas, M., Li, X., Babur, O., Hsu, T.-K., Lichtarge, O., et al. (2019) · Cell Reports · doi:10.1016/j.celrep.2019.07.001 · Cited by 710
The p53 Pathway in Glioblastoma
Zhang, Y., Dube, C., Gibert, M., Cruickshanks, N., Wang, B., Coughlan, M., Yang, Y., Setiady, I., Deveau, C., Saoud, K., et al. (2018) · Cancers · doi:10.3390/cancers10090297 · Cited by 440
TP53 Mutations in Human Cancer: Database Reassessment and Prospects for the Next Decade
Leroy, B., Anderson, M., & Soussi, T. (2014) · Human Mutation · doi:10.1002/humu.22552 · Cited by 408
p53 modifications: exquisite decorations of the powerful guardian
Liu, Y., Tavana, O., & Gu, W. (2019) · Journal of Molecular Cell Biology · doi:10.1093/jmcb/mjz060 · Cited by 392
Metadata
- Authors
- Nguyen, T.-A., Menendez, D., Resnick, M. A., & Anderson, C. W.
- Venue
- Human Mutation
- Publisher
- Wiley
- Published
- 2014-02-11
- Volume
- 35
- Issue
- 6
- Pages
- 738-755
- ISSN
- 1059-7794
- Cited by
- 69
- References
- 32
- Language
- en
- Licence
- doi.wiley.com/10.1002/tdm_license_1.1 (tdm, 567 d)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.